GALECTO INC
NASDAQ: GLTO (Galecto, Inc.)
Kemas kini terakhir: 16 jam lalu28.91
0.55 (1.94%)
| Penutupan Terdahulu | 28.36 |
| Buka | 28.31 |
| Jumlah Dagangan | 117,610 |
| Purata Dagangan (3B) | 177,676 |
| Modal Pasaran | 1,741,540,480 |
| Harga / Buku (P/B) | 268.22 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 11 Aug 2025 |
| EPS Cair (TTM) | -15.40 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.53% |
| Nisbah Semasa (MRQ) | 9.62 |
| Aliran Tunai Operasi (OCF TTM) | -15.13 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -8.59 M |
| Pulangan Atas Aset (ROA TTM) | -35.94% |
| Pulangan Atas Ekuiti (ROE TTM) | -88.35% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Menaik |
| Biotechnology (Global) | Menaik | Menaik | |
| Stok | Galecto, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 0.0 |
| Purata | -0.63 |
|
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 3.69% |
| % Dimiliki oleh Institusi | 13.02% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |